Q4 2023 · 13F-HR
Pennant Investors, LPholdings as filed
Filed 2024-02-14 · accession 0000919574-24-001300
$458.1M
Reported value
44
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 037833100 | AAPL | APPLE INC | $121.3M | 26.5% | 630,000 | PUT | SOLE |
| 023135106 | AMZN | AMAZON COM INC | $52.9M | 11.5% | 348,000 | Common | SOLE |
| 02079K305 | GOOGL | ALPHABET INC | $52.4M | 11.4% | 375,000 | Common | SOLE |
| 594918104 | MSFT | MICROSOFT CORP | $48.5M | 10.6% | 129,000 | Common | SOLE |
| 893641100 | TDG | TRANSDIGM GROUP INC | $42.5M | 9.28% | 42,000 | Common | SOLE |
| 278768106 | SATS | ECHOSTAR CORP | $35.7M | 7.79% | 2,153,209 | Common | SOLE |
| 595112103 | MU | MICRON TECHNOLOGY INC | $26.1M | 5.70% | 306,000 | Common | SOLE |
| 88337F105 | ODP1 | THE ODP CORP | $22.5M | 4.92% | 400,000 | Common | SOLE |
| 03674X106 | AR | ANTERO RESOURCES CORP | $20.7M | 4.52% | 913,000 | Common | SOLE |
| 03674X106 | AR | ANTERO RESOURCES CORP | $11.3M | 2.48% | 500,000 | CALL | SOLE |
| L7579L106 | — | PERIMETER SOLUTIONS SA | $10.6M | 2.31% | 2,300,000 | Common | SOLE |
| 02155H200 | ALT | ALTIMMUNE INC | $1.2M | 0.27% | 109,800 | Common | SOLE |
| 31572Q808 | FGENEUR | FIBROGEN INC | $681,033 | 0.15% | 768,400 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $586,176 | 0.13% | 56,800 | Common | SOLE |
| 19249H103 | CHRS | COHERUS BIOSCIENCES INC | $559,773 | 0.12% | 168,100 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $552,007 | 0.12% | 170,900 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $546,414 | 0.12% | 146,100 | Common | SOLE |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $539,319 | 0.12% | 64,900 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $508,053 | 0.11% | 186,100 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $501,642 | 0.11% | 55,800 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $497,065 | 0.11% | 44,500 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $490,860 | 0.11% | 32,400 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $466,824 | 0.10% | 42,400 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $452,670 | 0.10% | 23,700 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $421,356 | 0.09% | 43,800 | Common | SOLE |
| 03969T109 | ARCT | ARCTURUS THERAPEUTICS HLDGS | $413,043 | 0.09% | 13,100 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $412,164 | 0.09% | 128,400 | Common | SOLE |
| 81750R102 | MCRB1EUR | SERES THERAPEUTICS INC | $409,220 | 0.09% | 292,300 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $402,093 | 0.09% | 38,700 | Common | SOLE |
| 00847G705 | AGENEUR | AGENUS INC | $388,782 | 0.08% | 469,600 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $379,225 | 0.08% | 17,500 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $354,006 | 0.08% | 166,200 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $336,277 | 0.07% | 15,100 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $330,291 | 0.07% | 35,100 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $328,345 | 0.07% | 48,500 | Common | SOLE |
| 37427G101 | GETR | GETAROUND INC | $316,816 | 0.07% | 1,348,153 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $310,440 | 0.07% | 199,000 | Common | SOLE |
| 670002401 | NVAX | NOVAVAX INC | $289,440 | 0.06% | 60,300 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $257,115 | 0.06% | 30,500 | Common | SOLE |
| 09075P105 | BTAIEUR | BIOXCEL THERAPEUTICS INC | $247,505 | 0.05% | 83,900 | Common | SOLE |
| 019818103 | — | ALLOVIR INC | $146,633 | 0.03% | 215,700 | Common | SOLE |
| 09609G100 | — | BLUEBIRD BIO INC | $120,612 | 0.03% | 87,400 | Common | SOLE |
| 00951K104 | — | AIRSPAN NETWORKS HOLDINGS IN | $94,273 | 0.02% | 1,047,473 | Common | SOLE |
| G4124C117 | GRABW | GRAB HOLDINGS LIMITED | $17,984 | 0.00% | 80,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.